Seongnam, South Korea

Heui Ran Lee

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Industry-Academic Cooperation Foundation, Dankook University. Active years: 2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Heui Ran Lee. Retrieved from https://idiyas.com/inventor/heui-ran-lee

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2015

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Heui Ran Lee and a Tenascin C Peptide Aptamer

Introduction

Heui Ran Lee is an inventor associated with Seongnam, South Korea. His work includes a patent for a peptide aptamer designed to bind tenascin C, a target relevant to tumor imaging and diagnosis.

Latest Patents

Lee is associated with 1 patent: “Peptide Aptamers Against Tenascin C.” The invention describes an anti-tenascin C peptide aptamer with a specific amino acid sequence and a diagnostic kit containing the aptamer. According to the patent description, its small molecular weight supports rapid clearance, while its specific binding affinity to tenascin C offers potential advantages for in vivo and ex vivo tumor imaging.

Career Highlights

Lee is associated with the Industry-Academic Cooperation Foundation at Dankook University. The available information identifies his patent work but does not provide further details about his professional history.

Collaborations

The listed coworkers associated with Lee are Mee Young Kim and Kee Rang Park.

Conclusion

Heui Ran Lee’s patent focuses on a tenascin C-targeting peptide aptamer with potential applications in tumor imaging and diagnosis.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…